JP2009532388A5 - - Google Patents

Download PDF

Info

Publication number
JP2009532388A5
JP2009532388A5 JP2009503378A JP2009503378A JP2009532388A5 JP 2009532388 A5 JP2009532388 A5 JP 2009532388A5 JP 2009503378 A JP2009503378 A JP 2009503378A JP 2009503378 A JP2009503378 A JP 2009503378A JP 2009532388 A5 JP2009532388 A5 JP 2009532388A5
Authority
JP
Japan
Prior art keywords
oil
drug delivery
delivery composition
composition according
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009503378A
Other languages
English (en)
Japanese (ja)
Other versions
JP5349290B2 (ja
JP2009532388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2007/000548 external-priority patent/WO2007112579A1/en
Publication of JP2009532388A publication Critical patent/JP2009532388A/ja
Publication of JP2009532388A5 publication Critical patent/JP2009532388A5/ja
Application granted granted Critical
Publication of JP5349290B2 publication Critical patent/JP5349290B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009503378A 2006-04-03 2007-04-03 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法 Expired - Fee Related JP5349290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39603106A 2006-04-03 2006-04-03
US11/396,031 2006-04-03
PCT/CA2007/000548 WO2007112579A1 (en) 2006-04-03 2007-04-03 Drug delivery composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013169662A Division JP5592547B2 (ja) 2006-04-03 2013-08-19 薬物送達組成物

Publications (3)

Publication Number Publication Date
JP2009532388A JP2009532388A (ja) 2009-09-10
JP2009532388A5 true JP2009532388A5 (enExample) 2010-05-20
JP5349290B2 JP5349290B2 (ja) 2013-11-20

Family

ID=38563052

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009503378A Expired - Fee Related JP5349290B2 (ja) 2006-04-03 2007-04-03 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法
JP2013169662A Expired - Fee Related JP5592547B2 (ja) 2006-04-03 2013-08-19 薬物送達組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013169662A Expired - Fee Related JP5592547B2 (ja) 2006-04-03 2013-08-19 薬物送達組成物

Country Status (6)

Country Link
US (1) US20190083399A9 (enExample)
EP (1) EP2010162A4 (enExample)
JP (2) JP5349290B2 (enExample)
CN (1) CN101453996B (enExample)
CA (1) CA2648278C (enExample)
WO (1) WO2007112579A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1912730A2 (en) * 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US20090130220A1 (en) 2007-11-20 2009-05-21 Johnson Pamela A Cosmetic composition having pomace olive oil
CN102188490B (zh) * 2011-04-12 2013-05-01 李信金 一种治疗阳痿早泄的药酒
KR101336411B1 (ko) * 2011-05-27 2013-12-04 한국식품연구원 쌀 추출물의 수면 장애, 불안 또는 우울증의 개선, 예방 또는 치료를 위한 신규 용도
US10918589B2 (en) * 2013-03-15 2021-02-16 John Robert Goepfert Personal-lubricating material and method for lubricant manufacture
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3256141A1 (en) * 2015-02-09 2017-12-20 Vereeken, Jose Multiparticulate formulation comprising herbal extracts
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
MX2019005217A (es) * 2019-05-03 2020-11-04 Eduardo Arciniega Vazquez Proceso de obtención de membranas poliméricas a partir de componentes de origen natural.
CN110124580B (zh) * 2019-05-30 2020-04-10 天津中澳嘉喜诺生物科技有限公司 一种茶树精油肠溶包衣小丸及其制备方法和应用
WO2022072099A1 (en) * 2020-09-30 2022-04-07 Eirgen Pharma, Ltd Immediate release dosage forms, methods of making and using
CN116869944A (zh) * 2023-08-15 2023-10-13 重庆士立德医药科技有限公司 一种托瑞米芬组合物及其制备方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
GB1359643A (en) * 1970-09-28 1974-07-10 Controlled Medications Controlled release medicament
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
TW209174B (enExample) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5760121A (en) * 1995-06-07 1998-06-02 Amcol International Corporation Intercalates and exfoliates formed with oligomers and polymers and composite materials containing same
JP3929522B2 (ja) * 1996-03-14 2007-06-13 塩野義製薬株式会社 難水溶性薬物の徐放性製剤
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US6261582B1 (en) * 1996-10-15 2001-07-17 C. R. Bard, Inc. Surgical method and composition therefor
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
EP1030651A4 (en) * 1997-11-12 2006-05-31 Boehringer Mannheim Pharm Corp NEW ORAL DOSAGE FORM FOR CARVEDILOL
JP3059149B2 (ja) * 1998-01-06 2000-07-04 エフ・ホフマン−ラ ロシユ アーゲー テトラヒドロリプスタチン含有組成物
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
DE19901692C2 (de) * 1999-01-18 2002-06-20 Gruenenthal Gmbh Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
WO2001052813A1 (en) * 2000-01-19 2001-07-26 Pharmaceutical Discovery Corporation Multi-spike release formulation for drug delivery
CA2404687A1 (en) * 2000-03-30 2001-10-11 Nemichand B. Jain Sustained release beadlets containing stavudine
ATE293477T1 (de) * 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2005506323A (ja) * 2001-09-05 2005-03-03 ベクトゥラ・リミテッド 経口送達用機能性散剤
IN191024B (enExample) * 2001-09-25 2003-09-13 J B Chemicals And Pharmaceutic
MXPA04002973A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
SI21301A (sl) * 2002-09-11 2004-04-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
JP2006514986A (ja) * 2002-12-13 2006-05-18 シラグ・アクチエンゲゼルシヤフト トラマドールおよびトピラメートを含んでなる制御放出調製物
IN192381B (enExample) * 2002-12-20 2004-04-10 Ranbaxy Lab
US7485322B2 (en) * 2002-12-24 2009-02-03 Lek Pharmaceuticals D.D. Modified release pharmaceutical composition
WO2004080444A2 (en) * 2003-03-10 2004-09-23 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
CN1452983A (zh) * 2003-05-20 2003-11-05 广州贝氏药业有限公司 复方双氯芬酸钠缓释制剂
ATE419841T1 (de) * 2003-09-03 2009-01-15 Pharmaton Sa Kapseln enthaltend wirkstoffpellets mit unterschiedlichen freisetzungsprofilen
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
RU2340331C2 (ru) * 2004-02-04 2008-12-10 Алембик Лимитед Форма пролонгированного высвобождения венлафаксина гидрохлорида
US20060003001A1 (en) * 2004-02-11 2006-01-05 John Devane Chronotherapeutic compositions and methods of their use
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US7727328B2 (en) * 2006-05-16 2010-06-01 Harsco Corporation Regenerated calcium aluminate product and process of manufacture

Similar Documents

Publication Publication Date Title
JP5592547B2 (ja) 薬物送達組成物
CA2798700C (en) Alcohol-resistant formulations
JP5911969B2 (ja) 心臓血管障害の治療方法
JP2012528134A (ja) 浮遊性放出制御医薬組成物
CN101472568A (zh) 含有活性成分的肠衣颗粒
US20090004284A1 (en) Controlled release tamsulosin hydrochloride formulation
US20090291137A1 (en) Solid oral form provided with a double release profile
CA2877190C (en) Medicament form for release of active ingredients
CN1713896B (zh) 球形体、其制备方法以及药物组合物
JP2012519726A (ja) 治療薬のパルス放出組成物
CN102626396B (zh) 一种美托洛尔缓释片剂及其制备方法
CA2750196C (en) Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
CN104490838B (zh) 一种骨架型缓控释片剂及其制备方法和应用
EP2568977A1 (en) Alcohol-resistant metoprolol-containing extended- release oral dosage forms
WO2004024128A2 (en) Modified release ketoprofen dosage form
CN102238944B (zh) 用于制备生物粘附压制基质的方法
US20130171256A1 (en) Alcohol-resistant extended release dosage forms comprising venlafaxine
US8980318B2 (en) Neramexane multiple unit dosage form
CN1242745C (zh) 豆腐果素的缓、控释制剂
CN110869007B (zh) 防滥用的口服固体剂型
WO2017037742A1 (en) Oral pharmaceutical composition of tizandine
JP2020524697A5 (enExample)
AU2013200211A1 (en) Pharmaceutical formulations for the treatment of overactive bladder